SnackableHealth® | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care
TribeMD
7 min read
October 29, 2025
Carregando conteúdo…
SnackableHealth®
Cardiology
Highlights
SnackableHealth® |Non-cardiac effects in HELIOS-B trial: gastrointestinal symptoms and quality-of-life signals discussed by Drs. Mike Gibson and Tony Urey
ASCO GU® 2026
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
SnackableHealth® |Non-cardiac effects in HELIOS-B trial: gastrointestinal symptoms and quality-of-life signals discussed by Drs. Mike Gibson and Tony Urey
ASCO GU® 2026
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer